BPS 2013 Proceedings

Boulder Peptide Symposium, 2013

Peptide Showcase

Brief 15 minute presentations from companies developing peptide therapeutics and related technologies. This rapid and compressed format is designed for quick introduction between symposium participants to new technologies, and companies. Each presentation is structured to highlight the value of the technology or therapeutic being offered and the business strategy.

Peter Mariner

Senior Scientist
Mosaic Biosciences

Controlled drug delivery with versatile polymer technology

Mark Wilson

Vice President of Business Development
Medincell

MedinCell – New Developments

Nazli Azimi

CEO
Bioniz

Selective Inhibition of Multiple Cytokines: A Novel Peptide-based Therapeutic Approach for Immune Di

Kristopher Josephson

Director, Molecular Biology
Ra Pharmaceuticals, Inc.

Discovery of Potent Macrocyclic Peptides for Drug Development

Nazli Azimi

CEO
Bioniz

Selective Inhibition of Multiple Cytokines: A Novel Peptide-based Therapeutic Approach for Immune Di

Justin Romanowski

Associate Director, Business Development
Enteris BioPharma

Enteris BioPharma, Enabling Oral Drug Delivery

John Thottathil

Chief Scientific Officer
LAT Pharma

Terlipressin Prodrugs: Outpatient Treatment for Ascites Due to Liver Cirrhosis

Jesse Paterson

Senior Director, Business Development at CQDM
Angiochem

Achieving Therapeutic Concentrations of Drugs and Biologics in Brain by Conjugation with Angiopeps

Elijah Bolotin

PharmaIN Corp

Enabling peptide therapeutics by PGC excipients: VIP example.elivery of Therapeutics

Mark Wilson

Vice President of Business Development
Medincell

MedinCell – New Developments

Terrence Norchi

President and CEO
Arch Therapeutics

Self Assembling Peptide: A Medical Device For Surgical Hemostasis

Randall Engler

Director Strategic Sales
Novozymes Biopharma

Controlled Half-Life Extension for Peptide Therapeutics

Peter Mariner

Senior Scientist
Mosaic Biosciences

Controlled drug delivery with versatile polymer technology

Jean Lachowicz

Unknown
Angiochem

Achieving Therapeutic Concentrations of Drugs and Biologics in Brain by Conjugation with Angiopeps

George Ehrlich

Senior Scientist
Hoffmann-La Roche, Inc.

Preparation and Characterization of Albumin Conjugates of a Truncated Peptide YY Analog for Half-Lif

Eike Hoffmann

Senior Scientist
Roche Diagnostics GmbH

Pk Modulation of Haptenylated Peptides via Non-Covalent Antibody Complexation

Abhijit Bhat

Director
CovX, Pfizer

Do Peptide Therapeutics have a place in a world of antibodies and small molecules?

Laurie Parker

Assistant Professor
Purdue University

Measuring intracellular kinase activity with peptide biosensors

John Thottathil

Independent Consultant
Pharma Biotech Drug Development

Taxane Drugs and Un-natural Amino Acids

John Amery

Senior Principal Scientist
Pfizer / Biotherapeutics Pharmaceutical Sciences

Analytical Considerations for a Peptide Conjugated Virus Like Particle

Nick Terrett

CSO
Ensemble Therapeutics

Why macrocycles are important for drug discovery: synthetic macrocycle IL17 antagonists

Oral Presentations in Scientific Sessions

The session topics for Scientific Program are Peptides in the Clinic, Drug Delivery, Chemistry of Complex Peptides, Spotlight on Discovery, and Peptide Showcase. Abstracts may be submitted via the Apply to Present page on the website. Submissions will be reviewed by the Scientific Advisory Board on a monthly basis and the speaker will be notified of a decision.

Presentation length: Format is 25-30 minutes slide presentation with 5-10 minutes for Q&A, with the exception of Peptide Showcase talks which are 10 minute slide presentations with 5 minutes for Q&A. Please confirm with your session chair to confirm the exact presentation length.

Invited Speakers: Speakers are requested to supply their presentation details 30 days after receiving an invitation to present.

Program Book Deadline: Final abstract and title must be provided no later than September 1st. No changes to the program are possible after this date.

Presentation Format: Oral presenters please provide your presentation slides to the A/V table on the day of your presentation.

Lodging: All speakers are requested to reserve their own room. Discount rates at the conference hotel are available until August 16th.

Registration: All speakers, excluding sponsored presentation speakers, receive a complimentary registration upon approval of the abstract.

Peptide Showcase Description

The Peptide Showcase is an opportunity for an individual or company to “showcase” new ideas, technology and pipeline assets. Priority shall be given to presentations from biotech and startup companies. Service providers and vendors are not eligible. Speakers in the session receive a complimentary event registration.

Posters

Posters can be presented on any topic relevant to peptides including original research, innovative products and technologies.

Eligibility- Any attendee (from academia, industry, biotech or vendor/sponsor) can present a poster. The presentation must contain original scientific thinking. To submit a poster go to the Submit a Poster link from the meeting menu. All submissions are reviewed on a rolling basis and will be notified of approval. September 1st is the last day to submit a poster abstract. Approved posters are published on the BPF website.

A 30 ” x 40″ board shall be provided with thumb tacks. Board will be on an easel and can be rotated for either landscape or portrait formats. Once you apply for a poster, you will get email confirmation that your poster was accepted. The poster session and number assignments will be emailed one week before the Symposium.

Poster boards shall be available for display from 8am to 8pm the day of your assigned poster session. See the program agenda for the poster session schedule.

Public Release

Every presentation at the Boulder Peptide Symposium is automatically recorded. Speakers are required to give consent for sharing of the presentation video with the peptide community.